CTSO Stock Financial Analysis - Cytosorbents Corporation (NasdaqCM) Stock

Overview

Cytosorbents Corporation, based in the United States, operates within the biotechnology sector, primarily focusing on critical care immunotherapy products. The company is renowned for its development of CytoSorb, a blood purification technology aimed at reducing the excessive immune response, often seen in severe inflammatory conditions like sepsis, burn injury, trauma, and during cardiac surgery using cardiopulmonary bypass. This flagship product, which holds approval in the European Union and other areas outside the U.S., addresses a significant unmet medical need. By leveraging its proprietary blood purification technology, Cytosorbents Corporation seeks to improve clinical outcomes associated with cytokine storm and other conditions where cytokine levels elevate drastically, thereby positioning itself as a pioneer in the medical technology field focused on mitigating critical illnesses.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Cytosorbents Corporation as of June 30, 2025 is 36.11 MM.
The operating income for Cytosorbents Corporation as of June 30, 2025 is -16.31 MM.
The net income for Cytosorbents Corporation as of June 30, 2025 is -9.87 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	36.11	-16.31	-9.87
2025-03-31	35.33	-16.02	-16.11
2024-12-31	35.59	-16.79	-20.72
2024-09-30	30.63	-22.87	-19.29
2024-06-30	30.05	-25.77	-26.15
2024-03-31	30.62	-28.71	-28.01
2023-12-31	31.08	-31.95	-29.25
2023-09-30	37.07	-27.54	-23.44
2023-06-30	36.37	-29.33	-26.45
2023-03-31	35.45	-30.99	-31.17
2022-12-31	34.69	-30.89	-32.81
2022-09-30	36.08	-33.95	-41.35
2022-06-30	37.73	-30.34	-35.56
2022-03-31	41.26	-28.07	-29.36
2021-12-31	43.17	-22.74	-24.56
2021-09-30	44.34	-15.82	-15.93
2021-06-30	45.13	-12.37	-10.36
2021-03-31	42.90	-10.01	-8.55
2020-12-31	41.00	-10.37	-7.84
2020-09-30	36.48	-13.17	-11.11

Income Statement: EPS

The earnings per share basic for Cytosorbents Corporation as of June 30, 2025 is -0.17.
The earnings per share diluted for Cytosorbents Corporation as of June 30, 2025 is -0.17.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-0.17	-0.17
2025-03-31	-0.29	-0.29
2024-12-31	-0.38
2024-09-30	-0.37	-0.37
2024-06-30	-0.52	-0.52
2024-03-31	-0.59	-0.59
2023-12-31	-0.65
2023-09-30	-0.53	-0.53
2023-06-30	-0.61	-0.61
2023-03-31	-0.71	-0.71
2022-12-31	-0.75
2022-09-30	-0.95	-0.95
2022-06-30	-0.82	-0.82
2022-03-31	-0.68	-0.68
2021-12-31	-0.57
2021-09-30	-0.37	-0.37
2021-06-30	-0.24	-0.24
2021-03-31	-0.21	-0.21
2020-12-31	-0.20
2020-09-30	-0.31	-0.31

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Cytosorbents Corporation as of June 30, 2025 is -9.78 MM.
The cash from investing activities for Cytosorbents Corporation as of June 30, 2025 is -0.60 MM.
The cash from financing activities for Cytosorbents Corporation as of June 30, 2025 is 6.90 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-9.78	-0.60	6.90
2025-03-31	-13.06	-0.59	16.73
2024-12-31	-14.43	-0.67	9.33
2024-09-30	-18.49	-0.68	21.37
2024-06-30	-21.24	-0.64	22.12
2024-03-31	-23.38	-0.38	13.22
2023-12-31	-21.66	-0.94	14.47
2023-09-30	-20.59	-1.01	7.26
2023-06-30	-22.12	-1.47	6.62
2023-03-31	-23.22	-6.29	5.68
2022-12-31	-28.23	-6.46	4.96
2022-09-30	-28.39	-7.92	-0.12
2022-06-30	-25.78	-8.22	0.47
2022-03-31	-19.78	-4.52	0.60
2021-12-31	-14.01	-4.28	0.72
2021-09-30	-9.57	-2.87	-14.35
2021-06-30	-8.72	-2.26	41.44
2021-03-31	-4.75	-1.77	48.54
2020-12-31	-5.61	-1.68	66.35
2020-09-30	-8.68	-1.81	82.27

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Cytosorbents Corporation as of June 30, 2025 is 5.50.
The p/tbv for Cytosorbents Corporation as of June 30, 2025 is 5.50.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		5.50	5.50
2025-03-31		4.21	4.21
2024-12-31		3.79	3.79
2024-09-30	-3.20	4.88	4.88
2024-06-30	-1.52	2.22	2.79
2024-03-31		2.17	2.61
2023-12-31	-2.48	3.14	3.14
2023-09-30	-3.12	3.42	3.42
2023-06-30	-4.77	5.13	6.05
2023-03-31	-4.46	4.13	4.72
2022-12-31	-1.64	1.73	1.73
2022-09-30		1.27	1.27
2022-06-30		1.72	1.88
2022-03-31	-5.65	2.22	2.40
2021-12-31	-11.44	2.58	2.58
2021-09-30	-34.02	4.74	4.74
2021-06-30
2021-03-31	-11.99	1.33	1.40
2020-12-31	-13.07	1.29	1.37
2020-09-30	-9.21	1.28	1.28

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Cytosorbents Corporation as of June 30, 2025 is -0.22.
The ebit (3y)/ev for Cytosorbents Corporation as of June 30, 2025 is -0.29.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-0.22	-0.29
2025-03-31	-0.31	-0.43
2024-12-31	-0.34	-0.48
2024-09-30	-0.29	-0.35
2024-06-30	-0.75	-0.80
2024-03-31	-0.71	-0.71
2023-12-31	-0.45	-0.51
2023-09-30	-0.37	-0.34
2023-06-30	-0.24	-0.20
2023-03-31	-0.26	-0.19
2022-12-31	-0.93	-0.53
2022-09-30	-1.19	-0.72
2022-06-30	-0.57	-0.38
2022-03-31	-0.29	-0.21
2021-12-31	-0.14	-0.13
2021-09-30	-0.04	-0.05
2021-06-30
2021-03-31	-0.20	-0.33
2020-12-31	-0.19	-0.34
2020-09-30	-0.41	-0.56

Management Effectiveness

The roa for Cytosorbents Corporation as of June 30, 2025 is -0.30.
The roe for Cytosorbents Corporation as of June 30, 2025 is -0.96.
The roic for Cytosorbents Corporation as of June 30, 2025 is -0.39.
The croic for Cytosorbents Corporation as of June 30, 2025 is 0.07.
The ocroic for Cytosorbents Corporation as of June 30, 2025 is -0.31.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.30	-0.96	-0.39	0.07	-0.31
2025-03-31	-0.40	-0.99	-0.47	0.05	-0.46
2024-12-31	-0.35	-0.80	-0.47	0.05	-0.46
2024-09-30	-0.54	-1.38	-0.55	0.00	-0.46
2024-06-30	-0.48	-0.95	-0.75	-0.29	-0.64
2024-03-31	-0.45	-0.81	-0.69	-0.20	-0.52
2023-12-31	-0.38	-0.60	-0.64	-0.39	-0.56
2023-09-30	-0.37	-0.56	-0.63	-0.40	-0.52
2023-06-30	-0.44	-0.66	-0.63	-0.40	-0.52
2023-03-31	-0.39	-0.59	-0.66	-0.51	-0.49
2022-12-31	-0.43	-0.59	-0.79	-0.70	-0.54
2022-09-30	-0.37	-0.50	-0.79	-0.70	-0.54
2022-06-30	-0.30	-0.39	-0.58	-0.55	-0.42
2022-03-31	-0.28	-0.32	-0.42	-0.34	-0.29
2021-12-31	-0.18	-0.20	-0.32	-0.23	-0.11
2021-09-30	-0.10	-0.13	-0.19	-0.32	-0.10
2021-06-30	-0.21	-0.43	-0.12	0.35	-0.10
2021-03-31	-0.19	-0.40	-0.09	0.45	-0.05
2020-12-31	-0.29	-2.29	-0.08	0.62	-0.06
2020-09-30	-0.39	-1.65	-0.12	0.75	-0.09

Gross Margins

The gross margin for Cytosorbents Corporation as of June 30, 2025 is 0.69.
The net margin for Cytosorbents Corporation as of June 30, 2025 is -0.46.
The operating margin for Cytosorbents Corporation as of June 30, 2025 is -0.45.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.69	-0.46	-0.45
2025-03-31	0.63	-0.49	-0.55
2024-12-31	0.63	-0.49	-0.55
2024-09-30	0.65	-0.69	-0.65
2024-06-30	0.64	-0.75	-0.74
2024-03-31	0.62	-0.78	-0.86
2023-12-31	0.62	-0.63	-0.75
2023-09-30	0.57	-0.73	-0.82
2023-06-30	0.56	-0.73	-0.82
2023-03-31	0.60	-0.88	-0.89
2022-12-31	0.64	-1.15	-0.94
2022-09-30	0.71	-1.15	-0.94
2022-06-30	0.73	-0.94	-0.80
2022-03-31	0.74	-0.71	-0.68
2021-12-31	0.76	-0.57	-0.53
2021-09-30	0.75	-0.36	-0.35
2021-06-30	0.75	-0.23	-0.27
2021-03-31	0.72	-0.20	-0.25
2020-12-31		-0.19	-0.25
2020-09-30	0.71	-0.30	-0.36